3 (21) | |
Curettage | 1 (33) |
Partial resection | 2 (67) |
12 (86) | |
4 (33) | |
Single bone | 2 (50) |
MFB | 2 (50) |
8 (67) | |
Low risk | 3 (38) |
High risk | 5 (62) |
1 (7) | |
Remission | 10 (71) |
Reactivation/progressive | 4 (29) |
On therapy | 3 (75) |
Off therapy | 1 (25) |
ANED | 10 (72) |
AWD | 2 (14) |
DWD | 2 (14) |
1.7 | Female | MS | Skin, bone | Liver, spleen, hematopoietic | No | CMT | Ara-C, Pred | Progressive | DWD | 1 | |
0.25 | Female | MS | Lung, bone | Liver, spleen, hematopoietic | No | CMT | DAL-Hx83 | Remission | ANED | 16 | |
1.2 | Female | MS | Bone, LN | Liver, spleen | No | CMT | LCH-III | Reactivation MFB | AWD | 8.6 | |
15.6 | Male | MS | Lung, MFB (vertebrae) | Liver, spleen | No | CMT | LCH-IV | Reactivation | AWD | 2.7 | |
1.3 | Female | MS | Skin, bone | Liver, spleen, hematopoietic | No | CMT | LCH-IV | Progressive | DWD | 0.6 | |
9 | Female | SS | Bone | – | No | RT, CMT | CTX, VCR, Pred | Remission | ANED | 12 | |
0.5 | Female | SS | Skin | – | No | Observation | – | Remission | ANED | 12 | |
3 | Female | SS | Bone (CNS risk) | – | No | Curettage, CMT | LCH-III | Remission | ANED | 15 | |
8 | Female | MS | MFB, pituitary | – | Yes | CMT | LCH-III | Remission | ANED | 3 | |
7 | Female | SS | Bone | – | No | Surgery | – | Remission | ANED | 1 | |
10 | Male | SS | MFB | – | No | CMT | LCH-III | Remission | ANED | 6 | |
2 | Female | MS | Skin, pituitary, bone | – | Yes | CMT | LCH-III | Remission | ANED | 9 | |
10.25 | Male | MS | Bone (vertebrae), LN | – | No | Surgery, CMT | LCH-III | Remission | ANED | 8 | |
1.4 | Female | SS | MFB | – | No | CMT | LCH-IV | Remission | ANED | 0.5 |
1.7 | Female | TP 4.8 Alb |
Liver, spleen, hematopoietic | Skin, bone | Ara-C, Pred | Progressive | DWD | 1 | Not done | |
0.25 | Female | TP 8 Alb |
Liver, spleen, hematopoietic | Lung, bone | DAL-Hx83: VBL, VP-16, 6-MP, MTX, Pred | Remission | ANED | 16 | Not done | |
1.2 | Female | – | Liver, spleen | Bone, LN | LCH-III (High risk): MTX, VBL, Pred, 6-MP | Reactivation MFB | AWD | 8.6 | Not done | |
15.6 | Male | – | Liver, spleen | Lung, bone (special site) | LCH-IV adapted: (High risk): VBL, Pred, 6-MP | Reactivation | AWD | 2.7 | Negative | |
1.3 | Female | TP 6.27 |
Liver, spleen, hematopoietic | Skin, bone | LCH-IV adapted: (High risk): VBL, Pred, 6-MP | Progressive | DWD | 0.6 | Positive |
Normal | 3 (21) |
Abnormal | 11 (79) |
8 (73) | |
Normal | 1 (13) |
Abnormal | 7 (88) |
3 (27) | |
Done | 9 (64) |
Not done | 5 (36) |
Done | 4 (29) |
Not done | 10 (71) |
Age at diagnosis (years) | |
Median (range) | 2.5 (0.25–15.6) |
Mean ± SD | 5.1 ± 4.8 |
Sex | |
Female | 11 (79) |
Male | 3 (21) |
DI at diagnosis | 2 (14) |
System involvement | |
SS | 6 (43) |
Skin only | 1 (17) |
Single bone | 3 (50) |
MFB | 2 (33) |
MS | 8 (57) |
Low risk | 3 (38) |
High risk | 5 (63) |
Follow-up (years) | |
Median (range) | 6.8 (0.5–16.2) |
Mean ± SD | 6.9 ± 5.7 |